Angela Mariotto
#79,207
Most Influential Person Now
Statistician
Angela Mariotto's AcademicInfluence.com Rankings
Angela Mariottomathematics Degrees
Mathematics
#7183
World Rank
#9814
Historical Rank
Statistics
#800
World Rank
#888
Historical Rank
Download Badge
Mathematics
Angela Mariotto's Degrees
- PhD Statistics Stanford University
- Masters Mathematics University of California, Berkeley
- Bachelors Mathematics University of California, Berkeley
Similar Degrees You Can Earn
Why Is Angela Mariotto Influential?
(Suggest an Edit or Addition)According to Wikipedia, Angela Bacelar Mariotto is a statistician who researches the development and improvement of cancer progress measures. She is chief of the data analytics branch at the National Cancer Institute. Mariotto was a researcher at the Istituto Superiore di Sanità.
Angela Mariotto's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- SEER Cancer Statistics Review, 1975-2003 (2006) (8951)
- Cancer treatment and survivorship statistics, 2016 (2016) (5052)
- Cancer treatment and survivorship statistics, 2012 (2012) (3291)
- Cancer treatment and survivorship statistics, 2019 (2019) (2715)
- Projections of the cost of cancer care in the United States: 2010-2020. (2011) (2250)
- Cancer treatment and survivorship statistics, 2014 (2014) (2228)
- Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer (2014) (1622)
- SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) (2012) (1394)
- SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, (2006) (1382)
- Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival (2017) (1061)
- Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. (2009) (749)
- Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States (2016) (730)
- Cost of care for elderly cancer patients in the United States. (2008) (649)
- Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care (2013) (587)
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality. (2020) (532)
- Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research (2011) (417)
- Adverse Events After Outpatient Colonoscopy in the Medicare Population (2009) (411)
- Quantifying the role of PSA screening in the US prostate cancer mortality decline (2008) (391)
- Improved estimates of cancer-specific survival rates from population-based data. (2010) (386)
- Cancer Survivors: A Booming Population (2011) (371)
- Survivors of Childhood Cancer in the United States: Prevalence and Burden of Morbidity (2015) (355)
- Comparison of SEER Treatment Data With Medicare Claims (2016) (334)
- Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States (2017) (325)
- Long-Term Survivors of Childhood Cancers in the United States (2009) (302)
- Cancer treatment and survivorship statistics, 2022 (2022) (231)
- Productivity costs of cancer mortality in the United States: 2000-2020. (2008) (230)
- Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship (2007) (215)
- Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics (2018) (193)
- Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. (2019) (189)
- Cancer survival: an overview of measures, uses, and interpretation. (2014) (168)
- Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials (2017) (159)
- Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. (2002) (158)
- Medical Care Costs Associated with Cancer Survivorship in the United States (2020) (143)
- Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies (2013) (139)
- Changing patterns in breast cancer incidence trends. (2006) (129)
- Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. (2013) (126)
- Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. (2014) (117)
- When do changes in cancer survival mean progress? The insight from population incidence and mortality. (2014) (112)
- The prostate cancer conundrum revisited (2012) (104)
- Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. (2008) (102)
- Estimates and projections of value of life lost from cancer deaths in the United States. (2008) (102)
- Cancer Intervention and Surveillance Modeling Network (CISNET) (2001) (97)
- Current and future utilization of services from medical oncologists. (2008) (93)
- Is prostate cancer different in black men? Answers from 3 natural history models (2017) (86)
- Expected population impacts of discontinued prostate‐specific antigen screening (2014) (84)
- Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey (2007) (84)
- Comparison of Approaches for Estimating Incidence Costs of Care for Colorectal Cancer Patients (2009) (76)
- Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death. (2014) (73)
- Improved survival time: What can survival cure models tell us about population‐based survival improvements in late‐stage colorectal, ovarian, and testicular cancer? (2008) (72)
- Projecting SEER cancer survival rates to the US: an ecological regression approach (2002) (71)
- The impact of PLCO control arm contamination on perceived PSA screening efficacy (2012) (69)
- The history and use of cancer registry data by public health cancer control programs in the United States (2017) (67)
- Comparison of Approaches for Estimating Prevalence Costs of Care for Cancer Patients: What Is the Impact of Data Source? (2009) (67)
- Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020 (2006) (66)
- Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. (2014) (65)
- Breast cancer survivors in the United States (2009) (60)
- Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies. (2014) (60)
- Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. (2006) (59)
- The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials (2018) (55)
- Cancer‐specific mortality, cure fraction, and noncancer causes of death among diffuse large B‐cell lymphoma patients in the immunochemotherapy era (2017) (54)
- Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients. (2013) (53)
- Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. (2011) (52)
- Estimating breast cancer‐specific and other‐cause mortality in clinical trial and population‐based cancer registry cohorts (2009) (52)
- Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. (2006) (51)
- Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients (2016) (49)
- Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care (2021) (45)
- Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). (2017) (45)
- The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing (2004) (43)
- Development of a prognostic model for six-month mortality in older adults with declining health. (2012) (41)
- An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. (2004) (41)
- Geographical, racial and socio-economic variation in life expectancy in the US and their impact on cancer relative survival (2018) (41)
- Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates (2002) (39)
- The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients (2012) (36)
- Burden of illness in adult survivors of childhood cancers (2010) (36)
- Economic Burden of Cancer in the US: Estimates, Projections, and Future Research (2011) (33)
- Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens (2020) (33)
- Productivity savings from colorectal cancer prevention and control strategies. (2011) (29)
- Comparing cancer care, outcomes, and costs across health systems: charting the course. (2013) (27)
- Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. (2019) (26)
- The prevalence of patients with colorectal carcinoma under care in the U.S. (2003) (23)
- Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer (2018) (23)
- Contributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States (2016) (23)
- Estimates of long‐term survival for newly diagnosed cancer patients (2006) (22)
- Geographic association between mammography use and mortality reduction in the US (2005) (22)
- Estimating the variance of cancer prevalence from population-based registries (2006) (19)
- Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer. (2014) (18)
- The impact of state-specific life tables on relative survival. (2014) (15)
- Differences in Cancer Survival with Relative versus Cause-Specific Approaches: An Update Using More Accurate Life Tables (2019) (14)
- The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. (2021) (14)
- Estimating complete prevalence of cancers diagnosed in childhood (2008) (14)
- Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities. (2013) (13)
- Correcting the Completeness BIAS of Observed Prevalence (1999) (13)
- Cancer-Attributable Medical Costs for Colorectal Cancer Patients by Phases of Care: What Is the Effect of a Prior Cancer History? (2020) (13)
- Incidence and survival of rare cancers in the US and Europe (2020) (13)
- Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States. (2013) (12)
- Breast cancer in Portugal: Temporal trends and age-specific incidence by geographic regions. (2018) (12)
- [Survival in gastric cancer patients in Campinas, São Paulo, Brazil]. (2006) (12)
- Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer (2020) (12)
- An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program (2020) (12)
- Estimation of the numbers of individuals living with metastatic cancer in the United States. (2022) (11)
- Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975‐2016 (2021) (11)
- Development and Utility of the Observational Research in Oncology Toolbox: Cancer Medications Enquiry Database-Healthcare Common Procedure Coding System (HCPCS). (2020) (11)
- Differences in cancer survival among white and black cancer patients by presence of diabetes mellitus: Estimations based on SEER‐Medicare‐linked data resource (2018) (10)
- Lifetime benefits and harms of PSA-based risk screening for prostate cancer. (2020) (9)
- Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. (2022) (8)
- New Opportunities for Cancer Health Services Research: Linking the SEER-Medicare Data to the Nursing Home Minimum Data Set (2018) (8)
- Population-based survival-cure analysis of ER-negative breast cancer (2010) (7)
- Risk Models for Individualized Prognosis in the Practice of Precision Oncology (2017) (7)
- Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries. (2020) (5)
- Reply to Annual Report to the Nation on the status of cancer, part II: Recent changes in prostate cancer trends and disease characteristics (2018) (5)
- Advancing the science of cancer cost measurement: challenges and opportunities. (2013) (5)
- Overview of US Prostate Cancer Trends in the Era of PSA Screening (2009) (5)
- Erratum. Cancer Survival: An Overview of Measures, Uses, and Interpretation. (2015) (5)
- Home Health Use Following a Cancer Diagnosis Among Patients Enrolled in Medicare Advantage and Traditional Medicare: Findings From the Newly Linked SEER-Medicare and Home Health OASIS Data. (2020) (5)
- Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada. (2020) (4)
- Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors (2020) (4)
- Estimating Chemotherapy Use Among Patients With a Prior Primary Cancer Diagnosis Using SEER-Medicare Data. (2020) (4)
- Accuracy and completeness of diagnosis codes for cancer metastasis on Medicare claims. (2013) (3)
- Current Estimates for 5 and 10 Year Relative Survival (2003) (3)
- Regional differences in tobacco smoking and lung cancer in Portugal in 2018: a population-based analysis using nationwide incidence and mortality data (2020) (3)
- Developments and challenges in statistical methods in cancer surveillance (2014) (3)
- Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients. (2020) (3)
- Assessment of Oncology Practice Billing Claims for Supplementing Chemotherapy: A Pilot Study in the Georgia SEER Cancer Registry. (2020) (3)
- Impact of including second and later cancers in cause‐specific survival estimates using population‐based registry data (2021) (2)
- Survivorship for Individuals Living With Advanced and Metastatic Cancers: National Cancer Institute Meeting Report (2022) (2)
- Analyzing discrete competing risks data with partially overlapping or independent data sources and nonstandard sampling schemes, with application to cancer registries (2019) (2)
- Rate of growth of AIDS epidemic in Europe: a comparative analysis. (1989) (2)
- Projecting the National Economic Burden of Colorectal Cancer for the U.S. Through the Year 2020 (2007) (2)
- Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries (2021) (2)
- Construction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts (2017) (1)
- Genetic testing and results in population-based breast cancer patients and ovarian cancer patients. (2018) (1)
- PS1-39: Diagnosis Codes for Cancer Metastasis on Medicare Claims Have Limited Accuracy and Completeness (2013) (1)
- Estimating the Number of Men Living with Metastatic Prostate Cancer in the United States. (2023) (1)
- Measuring progress against cancer in the Azores, Portugal: Incidence, survival, and mortality trends and projections to 2025. (2020) (1)
- Estimating life expectancy adjusted by self-rated health status in the United States: national health interview survey linked to the mortality (2022) (1)
- Cancer prevalence by phase of care: an indicator for assessing health service needs (2020) (1)
- Estimating the prevalence of cancer patients who have recurred (2012) (0)
- Comment on: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. Authors' reply (2003) (0)
- Empirical Bayes inference and the linear model (1989) (0)
- Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with renal or hepatic dysfunction (dysf): Real-world patient characteristics and outcomes. (2018) (0)
- Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software (2021) (0)
- Sensitivity of Medicare claims to identify recurrence. (2013) (0)
- The impact of PLCO control arm contamination on perceived PSA screening efficacy (2012) (0)
- Sensitivity of Bayes and empirical Bayes estimates (1990) (0)
- Workforce Caring for Cancer Survivors in the United States: Estimates and Projections of Utilization. (2022) (0)
- Issue information (2014) (0)
- The Impact of Improved Treatments on Survival of Adult US Leukemia Patients: 1990 - 2018. (2023) (0)
- ANALYSIS OF INCIDENCE AND MORTALITY TRENDS 2 . 1 Joinpoint modeling – is the trend changing ? (2014) (0)
- New research identifies cancer types with little survival improvements in adolescents and young adults (2021) (0)
- Improved population-based probability of developing cancer when direct estimates of the cancer-free population are available (2012) (0)
- Adverse Events After Outpatient Colonoscopy in the Medicare (2009) (0)
- Improved population-based probability of developing cancer when direct estimates of the cancer-free population are available (2012) (0)
- New research identifies cancer types with little survival improvements in adolescents and young adults (2021) (0)
- The Utility of Pathology Reports to Identify Persons With Cancer Recurrence (2021) (0)
- Breast and Colorectal Cancer Recurrence-Free Survival Estimates in the US: Modeling Versus Active Data Collection (2023) (0)
- Emergent renal and hepatic dysfunction (dys) in a real-world cohort of advanced melanoma (aMel) patients (pts) receiving first line (1L) immune checkpoint inhibitors (ICIs). (2018) (0)
This paper list is powered by the following services:
Other Resources About Angela Mariotto
What Schools Are Affiliated With Angela Mariotto?
Angela Mariotto is affiliated with the following schools:
